MRC1 and colorectal carcinoma: Among 32 CRC patients, the objective response rate (ORR) for 10 patients with d-MMR was 40%, while the ORR of MMR-proficient patients was 0% (Le et al., 2017); the disease control rates (DCRs) for the d-MMR and MMR-proficient patients were 90% and 11%, respectively (Le et al., 2017).